The Giant Cell Arteritis (Temporal Arteritis/Cranial Arteritis/Horton Disease) drugs in development market research report provides comprehensive information on the therapeutics under development for Giant Cell Arteritis (Temporal Arteritis/Cranial Arteritis/Horton Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Giant Cell Arteritis (Temporal Arteritis/Cranial Arteritis/Horton Disease). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Giant Cell Arteritis (Temporal Arteritis/Cranial Arteritis/Horton Disease) and features dormant and discontinued products.
GlobalData tracks seven drugs in development for Giant Cell Arteritis (Temporal Arteritis/Cranial Arteritis/Horton Disease) by seven companies/universities/institutes. The top development phase for Giant Cell Arteritis (Temporal Arteritis/Cranial Arteritis/Horton Disease) is phase ii with three drugs in that stage. The Giant Cell Arteritis (Temporal Arteritis/Cranial Arteritis/Horton Disease) pipeline has seven drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Giant Cell Arteritis (Temporal Arteritis/Cranial Arteritis/Horton Disease) pipeline products market are: Johnson & Johnson, AbbVie and Novartis.
The key targets in the Giant Cell Arteritis (Temporal Arteritis/Cranial Arteritis/Horton Disease) pipeline products market include Interleukin 6 Receptor Subunit Alpha (IL6R1 or Membrane Glycoprotein 80 or CD126 or IL6R), Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2), and Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2).
The key mechanisms of action in the Giant Cell Arteritis (Temporal Arteritis/Cranial Arteritis/Horton Disease) pipeline product include Interleukin 6 Receptor Subunit Alpha (IL6R1 or Membrane Glycoprotein 80 or CD126 or IL6R) Antagonist with two drugs in Pre-Registration. The Giant Cell Arteritis (Temporal Arteritis/Cranial Arteritis/Horton Disease) pipeline products include four routes of administration with the top ROA being Intravenous and two key molecule types in the Giant Cell Arteritis (Temporal Arteritis/Cranial Arteritis/Horton Disease) pipeline products market including Monoclonal Antibody, and Small Molecule.
Giant Cell Arteritis (Temporal Arteritis/Cranial Arteritis/Horton Disease) overview
Giant cell arteritis (GCA) is a form of vasculitis, a group of disorders that cause inflammation of blood vessels that affects the arteries of the head (especially the temporal arteries, located on each side of the head). It is also called as temporal arteritis (TA) or cranial arteritis or Horton’s syndrome.
For a complete picture of Giant Cell Arteritis (Temporal Arteritis/Cranial Arteritis/Horton Disease)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
